Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06538116 · ClinicalTrials.gov registry record · Phase 2
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
A Phase 2 study of Alzheimer Disease, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06538116 is a Phase 2 study of Alzheimer Disease that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 300 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06538116, a Phase 2 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mevidalen
Study Locations (20)
Florida
- JEM Research Institute - Atlantis
- Visionary Investigators Network - Aventura
- Excel Medical Clinical Trials, LLC Boca Raton dba Flourish Research - Boca Raton
- Vertex Clinical Research - Clermont
- Neuropsychiatric Research Center of Southwest Florida - Fort Myers
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Merritt Island Medical Research, LLC dba Flourish Research - Merritt Island
- Visionary Investigators Network - Miami
- Suncoast Clinical Research - New Port Richey - New Port Richey
- Renstar Medical Research - Ocala
- Charter Research, LLC - Orlando
- Progressive Medical Research - Port Orange
- Intercoastal Medical Group - Sarasota
- Brain Matters Research - Stuart
California
- Profound Research LLC At The Neurology Center of Southern California - Carlsbad
- Neuropain Medical Center - Fresno
- Catalina Research Institute - Montclair
- California Neuroscience Research, LLC - Sherman Oaks
Arizona
- Banner Alzheimer's Institute - Phoenix
Arkansas
- Baptist Health Center for Clinical Research LLC - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-08-26 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06538116
The ClinicalTrials.gov registry entry for NCT06538116 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (89% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06538116 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06538116 about?
NCT06538116 is a clinical study titled "A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease". The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and...
What is the current status of trial NCT06538116?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2024-08-26. Estimated completion is 2026-05.
What conditions does trial NCT06538116 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06538116?
The interventions under investigation include: Placebo (DRUG), Mevidalen (DRUG).
Who is sponsoring clinical trial NCT06538116?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06538116 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.